Key Takeaways
- Soft quarter, margin resilience: Total income declined 4% QoQ as falling raw material prices pulled product prices lower, yet margins improved slightly on the same dynamic.
- ATBS destocking cycle ending: The destocking effect that weighed on overall sales and ATBS is now almost over, with a good pickup in ATBS sales starting from the current month.
- Antioxidant ramp is the growth engine: Revenue from antioxidants is expected to double to ~₹250 crores next year, driven by meaningful market penetration despite weak global demand.
- Veeral Additives turning the corner: The acquired business, running at only 25% capacity, is expected to become value-attractive within six months as sales increase month on month.
- What to watch next quarter: Whether the ATBS demand recovery materializes by April, the pace of antioxidant capacity utilization, and the commissioning of the MEHQ-Guaiacol plant in March.
ATBS: Destocking, Pricing & Market Position
- Destocking over, demand returning: The destocking effect in ATBS is almost over; sales are seeing a pickup, and management expects demand to normalize in coming months based on customer indications.
- Price decline is input-cost driven, not structural: ATBS prices moved from $3.8 to $3.2-$3.3, but the earlier peak reflected elevated raw material costs and freight, both of which have since eased; freight costs are now rising again.
- Market share intact: Vinati has not lost market share, protected by long-term customer contracts spanning 15-20 years.
- Capacity expansion on track: ATBS expansion from 40,000 to 60,000 tonnes is expected to be completed by December 2024.
- Competitive dynamics opaque: When asked about new competitors adding ATBS capacity, management declined to comment directly, suggesting the analyst research export data independently.
Mutreja: "I think based on the demand outlook as well as the order book, you will see recovery, if not from Feb, March, definitely from April."
Antioxidants: The Growth Story
- Revenue doubling next year: Antioxidant revenue is expected to reach ₹100-120 crores in FY24 at 25% capacity utilization, then double to ~₹250 crores in FY25 as penetration deepens.
- Market weakness, company strength: The global antioxidant market has been weak for 15-18 months, yet Vinati has made meaningful penetration due to synergies from double backward integration.
- Full utilization in 2-3 years: Management expects to reach full capacity utilization within two to three years and is actively adding more antioxidants to the portfolio without additional capex, spreading fixed costs over higher volumes.
- Domestic vs export split: Out of 24,000-ton capacity, the target is ~8,000 tons for domestic sale and ~16,000 tons for export; India's total demand is 12,000-14,000 metric tons, of which Vinati expects to capture 60-70%.
Mutreja: "No, no, no. This INR100 to INR120 crores will be the antioxidant revenue in this entire financial year FY24. Then, next year I expect this revenue to double from INR120 to about INR250 crores."
Veeral Additives: From Dilutive to Accretive
- Merger mechanics: NCLT sanctioned the amalgamation of Veeral Additives into Vinati Organics effective 1st April 2021; comparative financials have been restated.
- Margin drag quantified: The merger knocked off ₹32 crores of interest income over two years (previously a loan on Vinati's books) and added ~₹15 crores per year in depreciation; butylphenol supplies that were at market value now become inter-unit transfers.
- Turning point ahead: Veeral Additives is running at only 25% capacity with sales increasing month on month; management expects it to become value-attractive within the next six months.
- Cost-side levers: A co-generation power unit is being invested in to reduce manufacturing costs at Veeral Additives.
Mutreja: "So, eventually, this from being value diluting, we hope for it to become value-attractive in the next six months or so."
New Product Pipeline & Capex
- OSBP & DSBP commissioned: The ortho-sec butyl phenol and di-sec butyl phenol plant was commissioned this quarter, with ~₹80 crores revenue expected at full capacity.
- VOPL capex program: Total capex of ~₹480 crores lined up; the MEHQ-Guaiacol plant is expected to be commissioned first by March 2024, with other products (4-methoxyacetophenone, isoamylene derivatives, anisole) coming in H2 FY25.
- Ramp-up timeline: First 2-3 months post-commissioning go into stabilization, sample testing and product approvals; no significant sales are expected in the first quarter or even first six months; meaningful revenue comes six months post-commissioning.
- Isobutylene integration: Isobutylene is largely used captively for ATBS, butyl phenols and other derivatives; capacity has been expanded to support downstream growth.
- Solar power expansion: Added 11 megawatts of solar power in FY24, with another 7 megawatts planned for Q4 FY25.
Margins & Balance Sheet
- Q3 margin dynamic: Revenue declined 4% QoQ as falling raw material prices pulled product prices lower, which paradoxically caused a slight improvement in margins.
- Sustainable margin reset: Management stated that previous ~30% margins were never sustainable, calling them a "golden period"; the long-term sustainable blended EBITDA margin is 25-27%, with 27% described as a decent margin for any manufacturing business.
- No debt: The company has no long-term debt and no working capital debt on the books.
- CWIP reduction: The half-yearly balance sheet reduction in capital work-in-progress was related to the OSBP and DSBP commissioning.
Mutreja: "Those margins were never sustainable. That is, you come across those golden periods few times as a manufacturer in any manufacturing business. And I always have maintained that on a long-term basis, margins around 27% for any manufacturing business is a decent margin."
Revenue Mix & Segment Trends
- ATBS still dominant: ATBS contributed 32% of nine-month revenue, slightly higher than the quarterly mix of 30%, reflecting its weight in the portfolio.
- IBB picking up: IBB sales picked up starting last quarter; next year is expected to deliver higher numbers than FY24.
- Butyl phenol momentum: The butyl phenol business has scaled up well and delivered decent growth this year; momentum is expected to continue next year.
- Customized products doubled: Customized products have scaled from ~₹75 crores to ~₹150 crores over the last two years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS demand recovery | Recovery visible in order book and demand outlook | If not Feb/March, definitely from April |
| ATBS capacity expansion | Expansion from 40,000 to 60,000 tonnes completed | December 2024 |
| Antioxidant revenue | Double from ₹100-120 cr to ~₹250 cr | FY25 |
| Antioxidant full utilization | Reach full capacity utilization | 2-3 years |
| Veeral Additives value accretion | Become value-attractive | Next 6 months |
| MEHQ-Guaiacol plant | Commissioned | March 2024 |
| VOPL other products | 4-MAP, isoamylene derivatives, anisole commissioned | H2 FY25 |
| Revenue CAGR | 15-20% CAGR, reaching ~₹3,000 cr | 3-5 years |
| Sustainable EBITDA margin | 25-27% blended | Long-term |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Total income | ₹457 cr, down 4% QoQ from ₹473 cr |
| EBITDA | ₹124 cr, up 7% QoQ from ₹115 cr |
| Profit after tax | ₹77 cr, up 6% QoQ from ₹72 cr |
| EBITDA margin | 27%, improved from 24% in Q2 FY24 |
| Revenue CAGR guidance | 15% to 20% over the next three years |
| ATBS revenue share | 30% of total income for the quarter, 32% for 9M FY24 |
| IBB revenue share | 20% of total income for the quarter, 18% for 9M FY24 |
| Butylphenols and IB derivatives revenue share | 20% of total income |
| Isobutylene revenue share | 10% of total income |
| Antioxidant and other products revenue share | 20% of total income |
| Antioxidant revenue | ₹100 cr to ₹120 cr expected for full FY24, at 25% capacity utilization |
| Antioxidant revenue guidance | ~₹250 cr expected for FY25, doubling from FY24 |
| ATBS capacity utilization | 60% to 65% on present 40,000-tonne capacity over 9M FY24 |
| IBB capacity utilization | ~65% for the year |
| ATBS market share | ~65% |
| ATBS price | $3.2–$3.3, management-corrected range |
| Customized products scale-up | ₹150 cr, doubled from ₹75 cr over the last couple of years |
| OSBP and DSBP revenue potential | ₹80 cr at full capacity |
| VOPL total capex | ₹480 cr for the basket of 5–6 niche specialty chemical products |
| New projects expected ROI | 15% to 20% |
| New projects blended margin | ~20% |
| MEHQ and Guaiacol combined capacity | 3,000 tonnes per annum, 2,000 tonnes MEHQ and 1,000 tonnes Guaiacol |
| Anisole capacity | 5,000 tonnes |
| 4-MAP capacity | 1,000 tonnes |
| TAA and PTAP combined capacity | ~10,000 tonnes |
| MEHQ and Guaiacol plant commissioning | March 2024 |
| Other VOPL products commissioning | Second half of FY25, around December 2024 |
| ATBS expansion completion | December 2024, capacity rising from 40,000 to 60,000 tonnes |
| Solar power capacity added in FY24 | 11 megawatts, taking total to 26 megawatts; another 7 megawatts planned in Q4 FY25 |
| Capex in current year | ₹240 cr to ₹300 cr |
| Capex for FY25 | ₹450 cr to ₹500 cr |
| Gross block addition from Veeral Additives amalgamation | ~₹300 cr |
| Depreciation from Veeral Additives | ~₹15 cr per year |
| Interest income knocked off from Veeral Additives loan | ₹32 cr over the last two years |
| Long-term debt | Nil, no working capital debt on books |
| Sustainable EBITDA margin guidance | 25% to 27% on a blended level |
| Revenue in 4–5 years | ~₹3,000 cr (per management), ~₹3,500 cr (per an analyst's math) |